Researchers from the University of Helsinki and HUS looked into how mutations in the KLHL6 gene affect diffuse large B-cell lymphoma, which is the most common type of lymphatic system cancer.
The KLHL6 protein is responsible for getting rid of extra and unneeded proteins within the cells. When this system is disrupted in many cancers, it promotes the growth of malignant cells.
The researchers discovered that the KLHL6 protein breaks down and disrupts the normal process of getting rid of unwanted proteins, leading to increased growth of the most common type of lymphoma.The B-cell receptor was studied and found that specific mutations can cause an increase in the number of these receptors.
According to Doctoral Researcher Leo Meriranta, MD, from the University of Helsinki, the B-cell receptor is an antibody located on the surface of B-lymphocytes. It is used by normal cells to detect and fight pathogens. However, in abnormal cells, the B-cell receptor becomes activated in a way that leads to tissue growth and the development of lymphoma.
Predicting poor treatment outcomes
During the study, it was discovered that the absence of the KLHL6 protein in some cancer patients could indicate poor treatment outcomes.Absolutely missing from cells. Experimentation in the lab demonstrated that the absence of KLHL6 in lymphoma cells significantly increased the number of B-cell receptors.
Sirpa Leppä, an Oncology Professor who leads the research group, emphasizes the clinical importance of KLHL6.
“Lymphoma cases in which the KLHL6 protein was missing had a poor prognosis. Identifying pathogenic mechanisms relevant to these patients is crucial for improving their prognoses through drug development,” Leppä explains.
Therapy customization’s growing significance
A BritThe University of Helsinki and HUS researchers, along with an Irish-American research group, both found similar results. This suggests that disrupting the KLHL6 protein may be significant in certain B-cell diseases. Meriranta, a researcher, believes that targeting therapies based on cancer biomarkers could improve treatment outcomes in the future. This new discovery could lead to more tailored therapies, as the abnormal amount and activity of the B-cell receptor can potentially be targeted with medication. However, further research is still necessary.
Ranta notes.
Diffuse large B-cell lymphoma
- Approximately 700 individuals in Finland are diagnosed with diffuse large B-cell lymphoma every year.
- The primary symptom is the enlargement of lymph nodes.
- Treatment for the disease involves immunochemotherapy, which is a combination of antibodies and cytostatic drugs.
- In about 33% of cases, the cancer is not successfully cured and can be fatal.
